How we approach Philadelphia chromosome‐positive acute lymphoblastic leukemia in children and young adults. Issue 10 (11th August 2020)

• Record Type: Journal Article
• Authors: Slayton, William B.; Schultz, Kirk R.; Silverman, Lewis B.; Hunger, Stephen P.
• Is Part Of: Pediatric blood & cancer. Volume 67:Issue 10(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-08-11
• Subjects: clinical trial -- hematopoietic stem cell transplant -- minimal residual disease -- Philadelphia chromosome -- tyrosine kinase inhibitor; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28543
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Treatment for children with Philadelphia chromosome‐positive acute lymphoblastic leukemia has changed radically over the past 20 years. This type of leukemia used to have dismal prognosis, but today cure rates have improved with combination of cytotoxic chemotherapy and a tyrosine kinase inhibitor such as imatinib or dasatinib, with hematopoietic stem cell transplant reserved for patients who are at high risk based on slow response to therapy or who relapse. Treating these patients can be challenging particularly if they are not enrolled on a clinical trial. Here, we describe our approach to these patients.